Overall, these data support the computational prediction that NOS2 (iNOS) serves as a shared molecular target of both EPO and SPO and demonstrate that both extracts can downregulate iNOS transcription and NO production in inflammatory and tumor cell contexts. The gene discussed is EPO; the disease is neoplasm.